ST. LOUIS , Aug. 8 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health(TM), today announced the endorsement of its trial for West Nile virus encephalitis by an authority in Emergency Medicine, Dr. Neal Handly.

Dr. Handly is Associate Director of Research for the Department of Emergency Medicine at Drexel University College of Medicine and a Fellow of the American Academy of Emergency Medicine. Dr. Handly chairs the Academy's Subcommittee on Information Technology.

Dr. Handly said, 'GenoMed's protocol is extremely exciting, since we're in the grip of another West Nile epidemic this summer without any known treatment. The Emergency Room is where these cases are seen first. It makes sense to have the ER be a partner in a clinical trial.'

Dr. Handly continued, 'Dr. Moskowitz uses safe medicines already familiar to every ER physician. What makes his approach appealing is the possibility that it may work for many viruses, including avian influenza and bioterrorist viral attacks. These last two scenarios are of special concern to the Emergency Medicine community.'

About Dr. Handly

Dr. Neal Handly is an Assistant Professor in the Department of Emergency Medicine at Drexel University College of Medicine in Philadelphia , PA. He was consulted to create a state-of-the-art ER this summer in Beirut , Lebanon but has been prevented from doing so by the current hostilities.

About GenoMed

Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, http://www.genomed.com , by clicking on the 'West Nile trial' link. An email address is required for clinical follow-up.

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases 'ought to,' 'should,' 'could,' 'may,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed, Inc.